{"id":24032,"date":"2025-02-07T18:48:26","date_gmt":"2025-02-07T17:48:26","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/02\/07\/selective-sting-activation-in-intratumoral-myeloid-cells-via-ccr2-directed-antibody-drug-conjugate-tak-500\/"},"modified":"2025-02-07T18:48:26","modified_gmt":"2025-02-07T17:48:26","slug":"selective-sting-activation-in-intratumoral-myeloid-cells-via-ccr2-directed-antibody-drug-conjugate-tak-500","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/02\/07\/selective-sting-activation-in-intratumoral-myeloid-cells-via-ccr2-directed-antibody-drug-conjugate-tak-500\/","title":{"rendered":"Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody Drug Conjugate TAK-500"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2025 Feb 7. doi: 10.1158\/2326-6066.CIR-24-0103. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>The tumor microenvironment (TME) in solid tumors contains myeloid cells that modulate local immune activity. STING signaling activation in these myeloid cells enhances local type I interferon (IFN) production, inducing an innate immune response that mobilizes adaptive immunity and reprograms immunosuppressive myeloid populations to drive antitumor immunity. Here, we generated TAK-500, an immune cell directed antibody drug conjugate (iADC), to deliver a STING agonist to CCR2+ human cells and drive enhanced antitumor activity relative to non-targeted STING agonists. Preclinically, TAK-500 triggered dose-dependent innate immune activation in vitro. In addition, a murine TAK-500 iADC surrogate enhanced innate and adaptive immune responses both in vitro and in murine tumor models. Spatially resolved analysis of CCR2 and immune cell markers in the TME of &gt;1,000 primary human tumors showed the CCR2 protein was predominantly expressed in intratumoral myeloid cells. Collectively, these data highlight the clinical potential of delivering a STING agonist to CCR2+ cells.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39918395\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20250207124825&amp;v=2.18.0.post9+e462414\">39918395<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0103\">10.1158\/2326-6066.CIR-24-0103<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2025 Feb 7. doi: 10.1158\/2326-6066.CIR-24-0103. Online ahead of print. ABSTRACT The tumor microenvironment (TME) in solid tumors contains myeloid cells that modulate local immune activity. STING signaling activation in these myeloid cells enhances local type I interferon (IFN) production, inducing an innate immune response that mobilizes adaptive immunity and reprograms immunosuppressive myeloid &#8230; <a title=\"Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody Drug Conjugate TAK-500\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/02\/07\/selective-sting-activation-in-intratumoral-myeloid-cells-via-ccr2-directed-antibody-drug-conjugate-tak-500\/\" aria-label=\"Read more about Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody Drug Conjugate TAK-500\">Read more<\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-24032","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/24032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=24032"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/24032\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=24032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=24032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=24032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}